····			al		1 100,000	70.7
FORM PTO-144	19 (Modified)	MAY, 1 0 TOO.	Attorney Docket No.: 15280-3171000S		Application No.: 09/381,497	
		ATIONS FOR	Applicant: FitzGerald et	al.		
APPLICANT'S INFORMATION SECLOSURES STATEMENT (Use several sheets if necessary)			Filing Date: September 20, 1999		Group: 1642	
Reference Desig	nation		U.S. PATENT DOCUME	NTS		Page 1
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
-					R	ECEIVE
						MAY 1 5 200
					TECH	CENTER 1600
	Ţ	FO	REIGN PATENT DOCU	MENTS		
	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)
AA AA	WO94/29350	22 Dec. 1994	PCT	J		
						·
					_	
				_		
	l	FUED ADT (Incl	uding Author, Title, Date	Partinent Pages	Ftc.)	
AB AB	J. DE KRUIF E	T AL.: "Biosynthules for immunoli	netically lipid-modified hun posomes." FEBS LETTER	nan scFv fragments	from phage display	libraries as , pages 232-236,
LA AC			orientation-dependent expr	ression of single ch	ain Fv containing ar	n engineered
	disulfide-stabilized bond in the framework regions." JOURNAL OF BIOCHEMISTRY, vol. 118, NO. 4, 1 October 1995, pages 825-831, XP002075145 Tokyo, Japan					
AD AD	E. MANSFIELD ET AL.: "Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies." BIOCONJUGATE CHEMISTRY, vol. 7, no. 5, September 1996, pages 557-563, XP002075147 Washington, DC, USA					
AE AE	E. MANSFIELD ET AL.: "Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors." BLOOD, vol. 90, no. 5, 1 September 1997, pages 2020-2026, XP002075148 New York, NY, USA					
LM AF	V. RAJAGOPAL ET AL.: "A form of anti-Tac(Fv) which is both single-chain and disulfide-stabilized for imaging CD25+ tumors." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 8, March 1997, page 27 XP002075144 USA see abstract #180					
AG AG	fusion protein fo	or activation of a	elopment of a humanized d cephalosporin doxorubicin 2075146 Baltimore, MD, U	prodrug." CANCE	anti-p185HER2 Fv- R RESEARCH, vo	betalactamase l. 55, NO. 1, 1
	, ,					
	1111	010		<i>A</i> 1		
EXAMINER	- 111h	MA	DATE CONSIDERED	3/24/6)		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.